• Richard Pratley, Xuan Guan, Richard J Moro, and Rodrigo do Lago.
• AdventHealth Translational Research Institute, Orlando, Fla. Electronic address: richard.pratley.md@AdventHealth.com.
• Am. J. Med. 2024 Feb 1; 137 (2S): S3S8S3-S8.

AbstractHeart failure (HF) affects an estimated 6 million American adults, and the prevalence continues to increase, driven in part by the aging of the population and by increases in the prevalence of diabetes. In recent decades, improvements in the survival of patients with HF have resulted in a growing number of individuals living longer with HF. HF and its comorbidities are associated with substantial impairments in physical functioning, emotional well-being, and quality of life, and also with markedly increased rates of morbidity and mortality. As a result, the management of patients with HF has a substantial economic impact on the health care system, with most costs arising from hospitalization. Clinicians have an important role in helping to reduce the burden of HF through timely diagnosis of HF as well as increasing access to effective treatments to minimize symptoms, delay progression, and reduce hospital admissions. Prevention and early diagnosis of HF will play a fundamental role in efforts to reduce the large and growing burden of HF. Recent advances in pharmacotherapies for HF have the potential to radically change the management of HF, offering the possibility of improved survival and quality of life for patients.Copyright © 2023. Published by Elsevier Inc.

13 keywords...

hide…